LIDDS's research collaboration with Uppsala University continues in order to evaluate more cancer indications for the NanoZolid® technology. Preclinical studies of NanoZolid® with the cytotoxin docetaxel show clear effects in the local treatment of lung cancer tumours, without causing the side effects in the laboratory animals that systemic treatment inflicts. The results are presented in a scientific article that has now been accepted for publication.
LIDDS has a successful collaboration with Uppsala University, the Department of Immunology, Genetics and Pathology (IGP), as well as with several other researchers and oncology specialists. Since the NanoZolid® technology enables controlled drug release for up to six months, it provides opportunities for the effective local treatment of various types of cancer tumours, with limited side effects.
A research article entitled: “Antitumoral effect and reduced systemic toxicity in mice after intra-tumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel” has now been accepted for publication in the prestigious scientific journal, European Journal of Pharmaceutics and Biopharmaceutics. The lead author of the scientific article is Dr. Marie Jeansson (IGP). Researchers at Uppsala University and Uppsala University Hospital who contributed to the project are co-authors of the article.
The promising findings constitute an important step for the continued pharmaceutical development of NanoZolid® with docetaxel for the treatment of lung cancer. The next step in the research is a Phase I trial in humans.
– We are very excited about the promising preclinical results in lung cancer and for the constructive collaboration with leading oncology researchers in Uppsala. Research collaborations, both preclinical and clinical, are key to securing our development projects and in order to eventually be able to license projects to interested pharmaceutical companies, says CEO Monica Wallter.
Docetaxel is one of the most widely used drugs for the treatment of cancer as it has indications for a range of different cancers. Global sales of docetaxel amount to approximately USD one billion. NanoZolid® with docetaxel, provides LIDDS with the opportunity to develop new patented products for a number of cancer indications.
For more information, please contact:
Monica Wallter, CEO, +46 (0) 737 07 09 22, e-mail: monica.wallter@liddspharma.com
The goal of LIDDS is to develop effective pharmaceutical products to treat various cancers with the patented drug development technology NanoZolid®, which releases the drug locally in close proximity to the tumour for optimum effect and with fewer side effects. NanoZolid® provides a controlled release of the drug, which is released over shorter or longer periods of time, reducing the number of doses. As NanoZolid® can integrate pharmaceutical substances that have already been approved by the authorities, the development risk is reduced, as well as the time and cost required to obtain market approval. The company's most advanced project – the prostate cancer product Liproca® Depot with 2-hydroxyflutamide – has shown positive results in clinical, Phase II trials without inducing the hormonal side effects associated with current tablet treatment. For more information, go to liddspharma.com. Redeye AB is a certified adviser to LIDDS.